How many 8-K filings has Alto Neuroscience, Inc. filed?

Alto Neuroscience, Inc. (ANRO) has 12 8-K (Current Event Report) filings on record, spanning Feb 2024 to Oct 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Alto Neuroscience, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Alto Neuroscience, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Alto Neuroscience, Inc. (ANRO) — 8-K Filings

All 8-K filings from Alto Neuroscience, Inc.. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

Alto Neuroscience 8-K: Agreements, Sales, and Other Events — Oct 20, 2025 Risk: medium
Alto Neuroscience, Inc. filed an 8-K on October 20, 2025, reporting on events as of October 19, 2025. The filing indicates the entry into and termination of mat
Alto Neuroscience Announces Director Changes — Jul 8, 2025 Risk: low
Alto Neuroscience, Inc. announced on July 3, 2025, the departure of Director Dr. David Kupfer and the appointment of Dr. Michael R. Liebowitz as a new director.
Alto Neuroscience Files 8-K Report — Jun 26, 2025 Risk: low
On June 26, 2025, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
Alto Neuroscience Files 8-K — Jun 3, 2025 Risk: medium
On May 31, 2025, Alto Neuroscience, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
Alto Neuroscience Files 8-K — Feb 12, 2025 Risk: low
Alto Neuroscience, Inc. filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing does not contain specific financial figur
Alto Neuroscience Files 8-K with Definitive Agreement Update — Feb 3, 2025 Risk: medium
Alto Neuroscience, Inc. filed an 8-K on February 3, 2025, reporting an entry into a material definitive agreement and providing updates on its results of operat
Alto Neuroscience Files 8-K: Material Agreement & Equity Sales — Jan 16, 2025 Risk: medium
On January 13, 2025, Alto Neuroscience, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported unr
Alto Neuroscience Files 8-K Report — Oct 22, 2024 Risk: low
On October 22, 2024, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No speci
Alto Neuroscience Files 8-K: Material Agreement & Equity Sales — Jul 29, 2024 Risk: medium
On July 24, 2024, Alto Neuroscience, Inc. entered into a Material Definitive Agreement, creating a direct financial obligation. The company also reported on unr
Alto Neuroscience Appoints New Chief Medical Officer — May 21, 2024 Risk: medium
Alto Neuroscience, Inc. announced on May 21, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller, previously a Senior Medical D
Alto Neuroscience Appoints New CMO, Adds Director — Mar 11, 2024 Risk: medium
Alto Neuroscience, Inc. announced on March 8, 2024, the appointment of Dr. David Kupfer as Chief Medical Officer and the election of Ms. Jennifer McNeley to its
Alto Neuroscience Common Stock Lists on NYSE Under ANRO — Feb 6, 2024
Alto Neuroscience, Inc. filed an 8-K on February 6, 2024, to report that its common stock, with a par value of $0.0001 per share, is now registered on The New Y

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX